^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR E709G

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib. (PubMed, Respir Med Case Rep)
    After 2 months of afatinib treatment, significant tumor shrinkage was observed, and the patient's condition remained stable for 1 year. This case highlights the potential effectiveness of afatinib for treating rare stage IV lung adenocarcinoma with these specific EGFR mutations.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR E709G
    |
    Gilotrif (afatinib)
    2years
    Biomarker Analysis from a Phase II Alternating Therapy with Osimertinib and Afatinib for EGFR-Mutated NSCLC (WJOG10818L) (IASLC-ACLC 2022)
    Alternating therapy with osimertinib and afatinib for treatment-naïve patients with EGFR-mutated advanced NSCLC demonstrated encouraging efficacy. The advantages of this therapy are prevention of acquired resistance via secondary EGFR mutations, including T790M and C797S, and a broadened efficacy against various compound EGFR mutations.
    P2 data
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • HER-2 amplification • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR C797S • ERBB3 mutation • ERBB3 amplification • EGFR E709G
    |
    AVENIO ctDNA Surveillance Kit
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    4years
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. (PubMed, Clin Lung Cancer)
    No intra- or intertumor heterogeneity was observed for EGFR compound mutations. Our results indicate that both EGFR mutations were truncal and selective elimination of cancer cells with uncommon EGFR mutations is unrealistic.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR L858R • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719X + EGFR S768I • EGFR E709G • EGFR G719A + EGFR S768I • EGFR L858R + EGFR R776H • EGFR L858R + EGFR S768I
    over4years
    Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations. (PubMed, Hum Pathol)
    Furthermore, patients with compound mutations had significantly poorer prognoses than that of cases of single EGFR mutations (p=0.043). Overall, clinicopathological features of common, uncommon, and compound EGFR mutations are similar; however, tumors with compound mutations may be characterized by aggressive behavior and histological findings of clear cell features.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • NKX2-1 (NK2 Homeobox 1)
    |
    EGFR mutation • EGFR L858R • EGFR L858R + EGFR T790M • EGFR S768I • EGFR E709G • EGFR L858R + EGFR S768I